Here are three things to know:
1. The Phase 2 study evaluated the safety and efficacy of mirikizumab compared to placebo in patients who had previously failed conventional or biologic therapy for moderate-to-severe UC.
2. At 12 weeks:
- Between 11.5 and 22.6 percent of patients treated with mirikizumab achieved clinical remission, compared to 4.8 percent of those treated with placebo
- Between 41.3 and 59.7 percent of patients who received mirikizumab achieved clinical response, compared to 20.6 percent of those who treated with placebo
- Between 13.1-30.6 percent of patients treated with mirikizumab achieved endoscopic healing compared with 6.3 percent of patients treated with placebo
3. Mirikizumab is a humanized IgG4 monoclonal antibody which binds to the p19 subunit of interleukin 23. It is being studied for the treatment of immune diseases including psoriasis, ulcerative colitis and Crohn’s disease.
More articles on gastroenterology:
6 things to know about new AGA President Dr. David Lieberman
ASGE raising awareness of esophageal adenocarcinoma — 3 insights
